 - Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of MLN518 will be determined following review of their case by the Principal Investigator; because MLN518 is a substrate of the P-glycoprotein P-gp drug efflux pump, co- administration of agents that inhibit or induce this mechanism may alter exposure to MLN518 